Skip to Content
Merck
  • Low transferrin levels predict heightened inflammation in patients with COVID-19: New insights.

Low transferrin levels predict heightened inflammation in patients with COVID-19: New insights.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2021-12-25)
Catherine Claise, Jumana Saleh, Marwa Rezek, Sophie Vaulont, Carole Peyssonnaux, Marvin Edeas
ABSTRACT

Mounting evidence links hyperinflammation in gravely ill patients to low serum iron levels and hyperferritinemia. However, little attention has been paid to other iron-associated markers such as transferrin. The aim of this study was to investigate the association of different iron parameters in severe COVID-19 and their relation to disease severity. This study involved 73 hospitalized patients with positive test results for SARS-CoV-2. Patients were classified into two groups according to symptom severity: mild and severe. Blood levels of anti-SARS-CoV-2 antibodies, interleukin 6 (IL-6), C-reactive protein (CRP), and iron-related biomarkers were measured. The results revealed a significant increase in IL-6, CRP, and ferritin levels and decreased transferrin and iron levels in severe COVID-19. Transferrin negatively predicted variations in IgM and IgG levels (P < 0.001), as well as 34.4% and 36.6% increase in IL-6 and CRP levels, respectively (P < 0.005). Importantly, transferrin was the main negative predictor of ferritin levels, determining 22.7% of serum variations (P < 0.001). Reduced serum transferrin and iron levels, along with the increased CRP and high ferritin, were strongly associated with the heightened inflammatory and immune state in COVID-19. Transferrin can be used as a valuable predictor of increased severity and progression of the disease.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
apo-Transferrin human, ≥95% protein basis (biuret)